The 30-second answer
A credible peptide COA should match the exact lot, identify a traceable laboratory, show testing and report dates, explain the method, and distinguish purity from identity. HPLC alone can support a purity claim; it does not independently prove that the main peak is the peptide named on the vial.
As a regulatory benchmark, 21 CFR § 211.194 requires pharmaceutical laboratory records to identify the tested sample by source, quantity, lot number or distinctive code, dates, method, results, analyst authorization, and review.5 Research-use vendors are not automatically subject to this pharmaceutical CGMP rule; VialVerdict uses it as a benchmark for traceable documentation.
The VialVerdict framework
Nine checks before you trust the report
Match the lot or batch number
Non-negotiableThe report should identify the exact lot or batch sold on the product page or vial. A clean report for a different batch does not establish anything about the batch being offered.
Identify who ordered and who performed the test
High signalLook for the vendor or client name and the testing laboratory's legal name, address, report identifier, and contact details. A cropped chromatogram with no traceable lab is weak evidence.
Check the sample and report dates
Freshness checkA useful report shows when the sample was received or tested and when the report was issued. Dates should make sense for the lot currently on sale; an old report repeatedly attached to new inventory is a red flag.
Separate purity from identity
Most missedAn HPLC purity percentage describes the relative chromatographic signal under that method. It does not, by itself, prove that the main peak is the peptide named on the label. Identity needs a suitable identity procedure—commonly mass spectrometry or another selective method.
Read the method, not only the percentage
Context mattersLook for the analytical technique, instrument or method reference, sample preparation, detection conditions, and acceptance criteria. ICH and FDA guidance emphasize that an analytical procedure must be fit for its intended purpose and evaluated for characteristics such as specificity, accuracy, precision, range, and robustness.
Look for system suitability or quality controls
Method confidenceA result is stronger when the report or method indicates system-suitability checks, reference materials, calibration, blanks, controls, or replicate testing. A lone number without evidence that the system performed correctly is harder to trust.
Verify the laboratory independently
Do not trust the PDF aloneSearch the laboratory's own website, use its report-verification tool when available, and contact it using independently found details—not only a phone number printed on the document.
Check accreditation carefully
Useful, not magicalISO/IEC 17025 accreditation is a competence framework for testing and calibration laboratories. Confirm the accrediting body, certificate number, status, and—critically—whether the lab's accredited scope covers the relevant testing. A logo alone is not proof.
Treat one COA as one piece of evidence
Final ruleA COA does not replace vendor-history checks. Combine it with recent buyer reviews, transparent shipping and refund terms, a consistent testing archive, responsive support, and product-specific evidence.
What “99% HPLC purity” does—and does not—mean
HPLC separates components and measures detector response under a defined method. A 99% area result generally means the principal peak accounts for roughly 99% of the integrated chromatographic signal—not that the vial is 99% peptide by weight, sterile, correctly dosed, free of every contaminant, or confirmed as the claimed molecule.
USP researchers treat chromatographic purity and strength/assay as separate quality attributes and use mass-balance corrections for water, counterions, residual solvents, and inorganic residue.6 A reported HPLC area percentage is therefore not, by itself, proof of the milligrams of peptide in a vial.
ICH Q2(R2) treats identity, assay, purity, and impurity testing as distinct analytical purposes and emphasizes specificity/selectivity, accuracy, precision, range, and fitness for purpose.1 FDA guidance likewise separates identity, strength, quality, purity, and potency and expects methods to be suitable for their intended use.3
Purity and identity answer different questions
HPLC purity
Asks: how much of the detected chromatographic signal belongs to the principal peak under this method?
Identity testing
Asks: is the tested material consistent with the specific molecule claimed? LC/MS can combine separation with selective mass information.
ICH's LC/MS example uses selective mass detection together with retention time and recommends controls for interference, precision, accuracy, reportable range, and robustness.1 That is why a report containing both a defensible purity method and an appropriate identity method is more informative than an isolated HPLC percentage.
Red flags that should stop the comparison
- No lot or batch number
- The listed batch does not match the product
- No traceable laboratory identity
- No sample, test, or report date
- Only a cropped chromatogram or screenshot
- Purity presented as proof of identity
- No analytical method or acceptance criteria
- The same report reused across changing inventory
Frequently asked questions
Does 99% HPLC purity prove a peptide is authentic?
No. It indicates that the main chromatographic peak represented about 99% of the measured signal under the stated method. Identity, quantity, contamination, sterility, and batch matching are separate questions. A suitable identity test and traceable batch information are still needed.
Is HPLC the same as mass spectrometry?
No. HPLC separates components and can estimate purity under a defined method. Mass spectrometry measures mass-to-charge information and is commonly used as part of identity confirmation. The techniques answer different questions and are often more informative together.
Does ISO/IEC 17025 accreditation guarantee a result is correct?
No accreditation guarantees every result. ISO/IEC 17025 is evidence that a laboratory has been assessed for competence, but readers should verify that the accreditation is current and that its scope covers the relevant test.
What is the biggest peptide COA red flag?
A report that cannot be tied to the exact lot being sold. Other major red flags include an untraceable laboratory, missing dates, no method details, a purity claim presented as identity proof, and a reused report attached to multiple batches.
Primary sources
Claims in this guide are grounded in regulatory and standards guidance. These sources govern pharmaceutical-quality contexts; VialVerdict applies their analytical principles as a buyer due-diligence framework, not as a claim that research vendors are FDA-approved.
- 1. ICH Q2(R2): Validation of Analytical Procedures International Council for Harmonisation, 2023
- 2. Q2(R2) Validation of Analytical Procedures — Guidance for Industry U.S. Food and Drug Administration, 2024
- 3. Analytical Procedures and Methods Validation for Drugs and Biologics U.S. Food and Drug Administration, 2015
- 4. Laboratory Standard ISO/IEC 17025 Added to OSAC Registry National Institute of Standards and Technology, 2016
- 5. 21 CFR § 211.194 — Laboratory records Electronic Code of Federal Regulations
- 6. Reference Standards to Support Quality of Synthetic Peptide Therapeutics Pharmaceutical Research / U.S. Pharmacopeia, 2023